Weekly Investment Analysts’ Ratings Updates for Oruka Therapeutics (ORKA)

Several analysts have recently updated their ratings and price targets for Oruka Therapeutics (NASDAQ: ORKA):

• 10/7/2024 – Oruka Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $45.00 price target on the stock.
• 9/17/2024 – Oruka Therapeutics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 9/17/2024 – Oruka Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $44.00 price target on the stock.
• 9/16/2024 – Oruka Therapeutics is now covered by analysts at Lifesci Capital. They set an “outperform” rating and a $41.00 price target on the stock.
• 9/16/2024 – Oruka Therapeutics is now covered by analysts at TD Cowen. They set a “buy” rating on the stock.
• 9/13/2024 – Oruka Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $40.00 price target on the stock.
• 9/4/2024 – Oruka Therapeutics is now covered by analysts at Wedbush. They set an “outperform” rating and a $40.00 price target on the stock.
• 9/3/2024 – Oruka Therapeutics was upgraded by analysts at Wedbush to a “strong-buy” rating.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded up $0.29 on Monday, reaching $25.76. 76,237 shares of the company’s stock were exchanged, compared to its average volume of 51,849. Oruka Therapeutics, Inc. has a fifty-two week low of $18.72 and a fifty-two week high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Thursday, August 1st. The company reported ($25.92) earnings per share for the quarter. Equities analysts predict that Oruka Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.